Project Grant DP2AR085223
Award Date
9/4/24
Completion Date
8/31/27
Dollars Obligated
$1.7M
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This $169,560 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to characterize the cutaneous opioid circuitry and its role in regulating skin inflammation and sensation. The awardee, The Regents of the University of California, San Francisco, aims to identify the cellular sources of the endogenous opioid enkephalin and how it...
The National Institute on Drug Abuse awarded a $708,397 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Research Foundation For The State University Of New York, doing business as Stony Brook University. The grant, titled "The Spinal Cell Atlas of Opioid-Targeted Inflammasomes in the HIV Pain Model: Mechanism and Pathogenic Role," aims to investigate the role of inflammasomes in the development of opioid-induced hyperalgesia, a heightened pain...
This federal Project Grant award, valued at $238,276, was provided by the National Institute of Neurological Disorders and Stroke under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding supports research at the University of California, Irvine to investigate the role of the enzyme N-acylethanolamine acid amidase (NAAA) in the development of hyperalgesic priming, a model for studying the transition from acute to chronic pain. The project aims to identify the receptor...
This federal Project Grant award, totaling $1,612,516.00, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant, awarded on August 1, 2024, supports research at the University of Illinois focused on investigating the role of nicotinic acetylcholine receptors in neuropathic pain. The project aims to advance scientific understanding of the neural...
This federal Project Grant award for $173,799 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of the endogenous opioid system in pain and placebo analgesia. The research, to be conducted at the University of Pennsylvania, will use advanced in vivo imaging and optogenetic techniques to study the signaling dynamics and function of enkephalinergic neural populations in the ventrolateral periaqueductal...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $154,568 to The Washington University in St. Louis to investigate the role of endogenous opioids in the dorsal raphe nucleus (DRN) on motivational and affective behaviors during chronic pain. The primary objectives are to use dual-color 1-photon endoscopic imaging to examine how enkephalinergic and non-enkephalinergic neurons in the DRN...
This Project Grant award from the National Institutes of Health National Institute of Neurological Disorders and Stroke provides $4,036,400 to Drexel University to support research investigating immune modulating therapies for the treatment of Complex Regional Pain Syndrome (CRPS). The award period is from September 30, 2022 through August 31, 2025. The grant funds research aimed at elucidating mechanisms of T cell dysfunction in CRPS and investigating novel immune modulating therapies....
This federal Project Grant award, totaling $5,666,172, was issued by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to study the role of Schwann cell dysfunction and signaling pathways in the development of chemotherapy-induced painful peripheral neuropathy (CIPPN). Key objectives include examining the impact of peroxisome proliferator-activated receptor gamma (PPARγ) and low-density lipoprotein...
This federal Project Grant award of $2,223,769.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the combined impact of HIV infection and opioid use on inflammasome-mediated neuroinflammation and neurotoxicity. The overarching goal is to uncover the mechanistic intersection between HIV and opioids that heightens inflammation, in order to inform targeted interventions for improving cognitive impairment in...
This $2,370,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop advanced human pluripotent stem cell (HPSC) tools to create comprehensive, region-specific models for studying pain circuitry. The award to Trustees of Tufts College (Tufts University) supports three main objectives: 1) Developing scalable methods to generate region-specific sensory neurons and...